Myricx

Myricx Bio is focused on the development of novel antibody-drug conjugates (ADCs). ADCs are “biological missiles” that combine the targeting ability of antibodies with the toxicity of a chemotherapy drug payload. Myricx is developing a novel class of payloads for ADCs based on inhibition of N-Myristoyltransferase (NMT), an enzyme that is key to cancer cell survival. This distinct mechanism offers the potential to broaden the applicability of ADCs to cancer patients.